[Dihydropyrimidine dehydrogenase deficiency causes severe adverse effects of capecitabine].

Inoue, Hiroto; Sato, Yuto; Shintani, Shuuhei; Tanabe, Hiroki; Bamba, Hiromichi; Komai, Yasunobu; Nakamura, Tomoaki; Imai, Takayuki; Andou, Akira

Inoue, Hiroto; Sato, Yuto; Shintani, Shuuhei; Tanabe, Hiroki; Bamba, Hiromichi; Komai, Yasunobu; Nakamura, Tomoaki; Imai, Takayuki; Andou, Akira.

Afiliação

Inoue H; Department of Gastroenterology, Japanese Red Cross Nagahama Hospital.
Sato Y; Department of Gastroenterology, Japanese Red Cross Nagahama Hospital.
Shintani S; Department of Gastroenterology, Japanese Red Cross Nagahama Hospital.
Tanabe H; Department of Gastroenterology, Japanese Red Cross Nagahama Hospital.
Bamba H; Department of Gastroenterology, Japanese Red Cross Nagahama Hospital.
Komai Y; Department of Gastroenterology, Japanese Red Cross Nagahama Hospital.
Nakamura T; Department of Surgery, Japanese Red Cross Nagahama Hospital.
Imai T; Department of Gastroenterology, Shiga University of Medical Science.
Andou A; Department of Gastroenterology, Shiga University of Medical Science.

Nihon Shokakibyo Gakkai Zasshi ; 115(3): 290-298, 2018.

Article em Ja | MEDLINE | ID: mdl-29526981

Assuntos

Antimetabólitos Antineoplásicos/efeitos adversos; Capecitabina/efeitos adversos; Deficiência da Di-Hidropirimidina Desidrogenase/diagnóstico; Antimetabólitos Antineoplásicos/uso terapêutico; Capecitabina/uso terapêutico; Fluoruracila; Humanos; Masculino; Pessoa de Meia-Idade

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Deficiência da Di-Hidropirimidina Desidrogenase / Capecitabina / Antimetabólitos Antineoplásicos Tipo de estudo: Etiology_studies Limite: Humans / Male / Middle aged Idioma: Ja Ano de publicação: 2018 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google